BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15829331)

  • 1. Thalidomide in patients with malignant pleural mesothelioma.
    Baas P; Boogerd W; Dalesio O; Haringhuizen A; Custers F; van Zandwijk N
    Lung Cancer; 2005 May; 48(2):291-6. PubMed ID: 15829331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
    Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
    Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
    Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
    Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
    Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
    Pass HI; Brewer GJ; Dick R; Carbone M; Merajver S
    Ann Thorac Surg; 2008 Aug; 86(2):383-9; discussion 390. PubMed ID: 18640301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
    Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
    Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of vinflunine in malignant pleural mesothelioma.
    Talbot DC; Margery J; Dabouis G; Dark G; Taylor H; Boussemart H; Cadic V; Pinel MC; Rivière A; Ollivier L; Ruffié P
    J Clin Oncol; 2007 Oct; 25(30):4751-6. PubMed ID: 17947722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
    Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
    J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
    Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
    Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
    Hillerdal G; Sorensen JB; Sundström S; Vikström A; Hjerpe A
    Clin Respir J; 2008 Apr; 2(2):80-5. PubMed ID: 20298311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
    Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
    Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
    Vestermark LW; Larsen S; Lindeløv B; Bastholt L
    Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
    Gregorc V; Zucali PA; Santoro A; Ceresoli GL; Citterio G; De Pas TM; Zilembo N; De Vincenzo F; Simonelli M; Rossoni G; Spreafico A; Grazia Viganò M; Fontana F; De Braud FG; Bajetta E; Caligaris-Cappio F; Bruzzi P; Lambiase A; Bordignon C
    J Clin Oncol; 2010 May; 28(15):2604-11. PubMed ID: 20406925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
    Mathy A; Baas P; Dalesio O; van Zandwijk N
    Lung Cancer; 2005 Oct; 50(1):83-6. PubMed ID: 15951053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.